Daval International Limited   Report issue

For profit Phase 2
Founded: London United Kingdom (2000)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2008
NCT00769028
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

albumin (Human) (Plasbumin) (1 trial)

hyperimmune caprine serum (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Neoplasm Metastasis (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2